Patheon, a global provider of contract drug manufacturing and development services, raised $625 million by offering 29.8 million shares at $21, within the range of $19 to $22. Patheon plans to list on the NYSE under the symbol PTHN. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as lead managers on the deal.
